Youngun Kim

CTLA cytotoxic T-lymphocyte-associated protein DCR disease control rate HBV hepatitis B virus HCC hepatocellular carcinoma ICI Immune checkpoint inhibitor Nivo nivolumab Nivo/Ipi Nivolumab + Ipilimumab ORR objective response rate OS overall survival OSORR organ-specific objective response rate PD programmed cell death PFS progression-free survival PVTT portal vein tumor thrombosis Tregs regulatory T-cells 1 Introduction Immune checkpoint inhibitors (ICIs) have reshaped the treatment of...

Trawling for drivers of T cell exhaustion Although checkpoint blockade has markedly changed the landscape of cancer therapeutics, not all tumors are responsive to immunotherapy. Here, Kim et al. studied T cell exhaustion in two distinct types of colorectal cancers (CRCs), microsatellite instability–high (MSI) CRCs that are responsive to PD-1 blockade and microsatellite stable (MSS) CRCs that are resistant to PD-1 centric therapies.